{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:30:36Z","timestamp":1793205036925,"version":"4.5.0"},"publisher-location":"Cham","reference-count":92,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030326326","type":"print"},{"value":"9783030326333","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-32633-3_15","type":"book-chapter","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T11:05:29Z","timestamp":1590663929000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Alzheimer\u2019s Disease Therapeutic Approaches"],"prefix":"10.1007","author":[{"given":"Maria","family":"Revi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"R Anand","year":"2014","unstructured":"Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer\u2019s disease: past, present and future. Neuropharmacology 76:27\u201350","journal-title":"Neuropharmacology"},{"issue":"3","key":"15_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jnc.12306","volume":"126","author":"AS Anisuzzaman","year":"2013","unstructured":"Anisuzzaman AS, Uwada J, Masuoka T, Yoshiki H, Nishio M, Ikegaya Y, Takahashi N, Matsuki N, Fujibayashi Y, Yonekura Y, Momiyama T, Muramatsu I (2013) Novel contribution of cell surface and intracellular M1- muscarinic acetylcholine receptors to synaptic plasticity in hippocampus. J Neurochem 126(3):360\u2013371","journal-title":"J Neurochem"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.104.077172","volume":"312","author":"Y Aracava","year":"2005","unstructured":"Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (2005) Memantine blocks alpha7\u2217 nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312:1195\u20131205","journal-title":"J Pharmacol Exp Ther"},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/alzrt160","volume":"5","author":"A Atri","year":"2013","unstructured":"Atri A et al (2013a) Memantine in patients with Alzheimer\u2019s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 5:6","journal-title":"Alzheimers Res Ther"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/alzrt160","volume":"5","author":"A Atri","year":"2013","unstructured":"Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D (2013b) Memantine in patients with Alzheimer\u2019s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 5:6","journal-title":"Alzheimers Res Ther"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2008-13110","volume":"13","author":"S Bakchine","year":"2008","unstructured":"Bakchine S, Loft H (2008) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13:97\u2013107","journal-title":"J Alzheimers Dis"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1096\/fasebj.6.15.1464368","volume":"6","author":"MF Beal","year":"1992","unstructured":"Beal MF (1992) Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6:3338\u20133344","journal-title":"FASEB J"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/clpt.1983.222","volume":"34","author":"NL Benowitz","year":"1983","unstructured":"Benowitz NL, Kuyt F, Jacob P 3rd, Jones RT, Osman AL (1983) Cotinine disposition and effects. Clin Pharmacol Ther 34:604\u2013611","journal-title":"Clin Pharmacol Ther"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0149-7634(03)00070-8","volume":"27","author":"J Berger-Sweeney","year":"2003","unstructured":"Berger-Sweeney J (2003) The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. Neurosci Biobehav Rev 27:401\u2013411","journal-title":"Neurosci Biobehav Rev"},{"key":"15_CR10","doi-asserted-by":"crossref","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev (1):CD005593","DOI":"10.1002\/14651858.CD005593"},{"key":"15_CR11","first-page":"306","volume":"135","author":"ER Bowman","year":"1962","unstructured":"Bowman ER, Mc KH Jr (1962) Studies on the metabolism of (\u2212)-cotinine in the human. J Pharmacol Exp Ther 135:306\u2013311","journal-title":"J Pharmacol Exp Ther"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement 3:186\u2013191","journal-title":"Alzheimers Dement"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbr.2011.01.021","volume":"221","author":"E Bruel-Jungerman","year":"2011","unstructured":"Bruel-Jungerman E, Lucassen PJ, Francis F (2011) Cholinergic influences on cortical development and adult neurogenesis. Behav Brain Res 221:379\u2013388","journal-title":"Behav Brain Res"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1124\/mol.53.3.555","volume":"53","author":"B Buisson","year":"1998","unstructured":"Buisson B, Bertrand D (1998) Open-channel blockers at the human alpha4beta2neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555\u2013563","journal-title":"Mol Pharmacol"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","volume":"17","author":"DA Butterfield","year":"2003","unstructured":"Butterfield DA, Pocernich CB (2003) The glutamatergic system and Alzheimer\u2019s disease: therapeutic implications. CNS Drugs 17:641\u2013652","journal-title":"CNS Drugs"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/13543776.2013.769522","volume":"23","author":"S Collina","year":"2013","unstructured":"Collina S, Gaggeri R, Marra A, Bassi A, Negrinotti S, Negri F, Rossi D (2013) Sigma receptor modulators: a patent review. Expert Opin Ther Pat 23:597\u2013613","journal-title":"Expert Opin Ther Pat"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","volume":"49","author":"J Coyle","year":"2001","unstructured":"Coyle J, Kershaw P (2001) Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer\u2019s disease. Biol Psychiatry 49:289\u2013299","journal-title":"Biol Psychiatry"},{"issue":"4","key":"15_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"J Cummings","year":"2014","unstructured":"Cummings J et\u00a0al (2014) Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther 6(4):37","journal-title":"Alzheimers Res Ther"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1368-5031.2005.00769.x","volume":"60","author":"T Dantoine","year":"2006","unstructured":"Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I (2006) Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer\u2019s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 60:110\u2013118","journal-title":"Int J Clin Pract"},{"key":"15_CR20","unstructured":"Dementia Fact Sheet No 362. http:\/\/who.int\/mediacentre\/factsheets\/fs362\/en\/"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fphys.2012.00464","volume":"3","author":"MC Dinamarca","year":"2012","unstructured":"Dinamarca MC, Rios JA, Inestrosa NC (2012) Postsynaptic receptors for amyloidbetaoligomers as mediators of neuronal damage in Alzheimer\u2019s disease. Front Physiol 3:464","journal-title":"Front Physiol"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbr.2010.11.037","volume":"221","author":"BD Drever","year":"2011","unstructured":"Drever BD, Riedel G, Platt B (2011) The cholinergic system and hippocampal plasticity. Behav Brain Res 221:505\u2013514","journal-title":"Behav Brain Res"},{"key":"15_CR23","first-page":"614","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, Dekosky ST, Gauthier S, Selkoe D, Baterman R et al (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lacet Neurol 13:614\u2013629","journal-title":"Lacet Neurol"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1755-5949.2012.00317.x","volume":"18","author":"V Echeverria","year":"2012","unstructured":"Echeverria V, Zeitlin R (2012) Cotinine: a potential new therapeutic agent against Alzheimer\u2019s disease. CNS Neurosci Ther 18:517\u2013523","journal-title":"CNS Neurosci Ther"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3233\/JAD-2011-102136","volume":"24","author":"V Echeverria","year":"2011","unstructured":"Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, Mamcarz M, Wang L, Sattelle DB, Kirschner DA, Mori T, Leblanc RM, Prabhakar R, Arendash GW (2011) Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer\u2019s disease mice. J Alzheimers Dis 24:817\u2013835","journal-title":"J Alzheimers Dis"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1001\/jama.1992.03490180055026","volume":"268","author":"M Farlow","year":"1992","unstructured":"Farlow M, Gracon S, Hershey L, Lewis SC, DolanUreno J (1992) A controlled trial of tacrine in Alzheimer disease. J Am Med Assoc 268:2523\u20132529","journal-title":"J Am Med Assoc"},{"key":"15_CR27","doi-asserted-by":"publisher","unstructured":"Farrimond LE, Roberts E, McShane R (2012) Memantine and cholinesterase inhibitor combination therapy for Alzheimer\u2019s disease: a systematic review. BMJ Open 2. https:\/\/doi.org\/10.1136\/bmjopen-2012-000917","DOI":"10.1136\/bmjopen-2012-000917"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphiconsensus study. Lancet 366:2112\u20132117","journal-title":"Lancet"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","volume":"5","author":"A Fisher","year":"2008","unstructured":"Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer\u2019s disease. Neurotherapeutics 5:433\u2013442","journal-title":"Neurotherapeutics"},{"issue":"Suppl. 1","key":"15_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1471-4159.2011.07507.x","volume":"120","author":"A Fisher","year":"2012","unstructured":"Fisher A (2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer\u2019s disease. J Neurochem 120(Suppl. 1):22\u201333","journal-title":"J Neurochem"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12031-002-0025-3","volume":"19","author":"A Fisher","year":"2002","unstructured":"Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z (2002) AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer\u2019s disease. J Mol Neurosci 19:145\u2013153","journal-title":"J Mol Neurosci"},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.neuropharm.2009.01.012","volume":"56","author":"KE Gilling","year":"2009","unstructured":"Gilling KE, Jatzke C, Hechenberger M, Parsons CG (2009) Potency, voltage dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1\/GluN2A) receptors. Neuropharmacology 56:866\u2013875","journal-title":"Neuropharmacology"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","volume":"68","author":"J Godyn","year":"2016","unstructured":"Godyn J, Jonczyk J, Panec D, Malawska B (2016) Therapeutic strategies for Alzheimer\u2019s disease in clinical trials. Pharmacol Rep 68:127\u2013138","journal-title":"Pharmacol Rep"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","volume":"68","author":"WV Graham","year":"2017","unstructured":"Graham WV, Bonito-Oliva A, Sakmar TP (2017) Update on Alzheimer\u2019s disease. Therapy and prevention strategies. Annu Rev Med 68:413\u2013430","journal-title":"Annu Rev Med"},{"key":"15_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1046\/j.1471-4159.2000.740777.x","volume":"74","author":"E Hellstrom-Lindahl","year":"2000","unstructured":"Hellstrom-Lindahl E, Moore H, Nordberg A (2000) Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74:777\u2013784","journal-title":"J Neurochem"},{"key":"15_CR36","first-page":"651","volume":"27","author":"R Hellweg","year":"2012","unstructured":"Hellweg R, Wirth Y, Janetzky W, Hartmann S (2012) Efficacy of memantine in delaying clinical worsening in Alzheimer\u2019s disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int J GeriatrPsychiatry 27:651\u2013656","journal-title":"Int J GeriatrPsychiatry"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2174\/138945012800398973","volume":"13","author":"CM Hernandez","year":"2012","unstructured":"Hernandez CM, Dineley KT (2012) Alpha7 nicotinic acetylcholine receptors in Alzheimer\u2019s disease: neuroprotective, neurotrophic or both? Curr Drug Targets 13:613\u2013622","journal-title":"Curr Drug Targets"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius H, Neundorfer G (2003) The discovery of Alzheimer\u2019s disease. Dialogues Clin Neurosci 5:101\u2013108","journal-title":"Dialogues Clin Neurosci"},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O\u2019Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 366:893\u2013903","journal-title":"N Engl J Med"},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/archneurol.2009.46","volume":"66","author":"MD Ikonomovic","year":"2009","unstructured":"Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST (2009) Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 66:646\u2013651","journal-title":"Arch Neurol"},{"issue":"7","key":"15_CR41","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/aps.2013.7","volume":"34","author":"JY Jia","year":"2013","unstructured":"Jia JY, Zhao QH, Liu Y, Gui YZ, Liu GY, Zhu DY, Yu C, Hong Z (2013) Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine a, for the treatment of Alzheimer\u2019s disease. Acta Pharmacol Sin 34(7):976\u2013982","journal-title":"Acta Pharmacol Sin"},{"key":"15_CR42","doi-asserted-by":"publisher","first-page":"13541","DOI":"10.1074\/jbc.M008035200","volume":"276","author":"T Kihara","year":"2001","unstructured":"Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a beta-amyloid-induced neurotoxicity. J Biol Chem 276:13541\u201313546","journal-title":"J Biol Chem"},{"key":"15_CR43","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/bmj.322.7300.1447","volume":"322","author":"M Kivipelto","year":"2001","unstructured":"Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer\u2019s disease in later life: longitudinal population based study. BMJ 322:1447\u20131451","journal-title":"BMJ"},{"key":"15_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JAD-2012-120124","volume":"30","author":"A Klugman","year":"2012","unstructured":"Klugman A, Naughton DP, Isaac M, Shah I, Petroczi A, Tabet N (2012) Antioxidant enzymatic activities in Alzheimer\u2019s disease: the relationship to acetylcholinesterase inhibitors. J Alzheimers Dis 30:467\u2013474","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"15_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.pnpbp.2010.07.018","volume":"35","author":"A Kurz","year":"2011","unstructured":"Kurz A, Perneczky R (2011) Novel insights for the treatment of Alzheimer\u2019s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 35(2):373\u2013379","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"9","key":"15_CR46","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/npp.2013.70","volume":"38","author":"V Lahmy","year":"2013","unstructured":"Lahmy V, Meunier J, Malmstrom S, Naert G, Givalois L, Kim SH, Villard V, Vamvakides A, Maurice T (2013) Blockade of tau hyperphosphorylation and abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology 38(9):1706\u20131723","journal-title":"Neuropsychopharmacology"},{"key":"15_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040326","volume":"7","author":"RH Lee","year":"2012","unstructured":"Lee RH, Tseng TY, Wu CY, Chen PY, Chen MF, Kuo JS, Lee TJ (2012) Memantine inhibits alpha3beta2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries. PLoS One 7:40326","journal-title":"PLoS One"},{"key":"15_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/sj.clpt.6100242","volume":"83","author":"G Lefevre","year":"2008","unstructured":"Lefevre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, Maton S, Ereshefsky L, Pommier F, Schmidli H, Appel-Dingemanse S (2008) Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer\u2019s disease patients. Clin Pharmacol Ther 83:106\u2013114","journal-title":"Clin Pharmacol Ther"},{"key":"15_CR49","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","volume":"80","author":"OL Lopez","year":"2009","unstructured":"Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600\u2013607","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","volume":"40","author":"A Maelicke","year":"2010","unstructured":"Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK (2010) Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci 40:135\u2013137","journal-title":"J Mol Neurosci"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/sj.bjp.0705559","volume":"140","author":"PD Maskell","year":"2003","unstructured":"Maskell PD, Speder P, Newberry NR, Bermudez I (2003) Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl- D-aspartate receptors. Br J Pharmacol 140:1313\u20131319","journal-title":"Br J Pharmacol"},{"key":"15_CR52","doi-asserted-by":"crossref","unstructured":"McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev:CD003154","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"15_CR53","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajpath.2011.04.041","volume":"179","author":"R Medeiros","year":"2011","unstructured":"Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, Fisher A, LaFerla FM (2011) Loss of muscarinic M1 receptor exacerbates Alzheimer\u2019s disease-like pathology and cognitive decline. Am J Pathol 179:980\u2013991","journal-title":"Am J Pathol"},{"key":"15_CR54","first-page":"38e45","volume":"692","author":"JJ Miguel-Hidalgo","year":"2012","unstructured":"Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK (2012) Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40. Eur J Pharmacol 692:38e45","journal-title":"Eur J Pharmacol"},{"key":"15_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00002093-199903000-00003","volume":"13","author":"DE Moss","year":"1999","unstructured":"Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C (1999) Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 13:20\u201325","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"15_CR56","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/bcp.12018","volume":"75","author":"DE Moss","year":"2013","unstructured":"Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E (2013) A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer\u2019s disease. Br J Clin Pharmacol 75:1231\u20131239","journal-title":"Br J Clin Pharmacol"},{"key":"15_CR57","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1124\/jpet.110.174458","volume":"336","author":"M Motawaj","year":"2011","unstructured":"Motawaj M, Burban A, Davenas E, Arrang JM (2011) Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer\u2019s disease. J Pharmacol Exp Ther 336:479\u2013487","journal-title":"J Pharmacol Exp Ther"},{"key":"15_CR58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuint.2008.12.001","volume":"54","author":"M Mousavi","year":"2009","unstructured":"Mousavi M, Hellstrom-Lindahl E (2009) Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 54:237\u2013244","journal-title":"Neurochem Int"},{"key":"15_CR59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1159\/000343479","volume":"2","author":"T Muayqil","year":"2012","unstructured":"Muayqil T, Camicioli R (2012) Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer\u2019s disease and other dementias. Dement Geriatr Cogn Dis Extra 2:546\u2013572","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"15_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbr.2010.11.053","volume":"218","author":"K Nakaya","year":"2011","unstructured":"Nakaya K, Nakagawasai O, Arai Y, Onogi H, Sato A, Niijima F, Tan-No K, Tadano T (2011) Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav Brain Res 218:165\u2013173","journal-title":"Behav Brain Res"},{"key":"15_CR61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JAD-2012-121447","volume":"33","author":"R Ni","year":"2013","unstructured":"Ni R, Marutle A, Nordberg A (2013) Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer\u2019s disease brain. J Alzheimers Dis 33:841\u2013851","journal-title":"J Alzheimers Dis"},{"key":"15_CR62","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/1531-8249(200012)48:6<913::AID-ANA12>3.0.CO;2-S","volume":"48","author":"RM Nitsch","year":"2000","unstructured":"Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH (2000) The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol 48:913\u2013918","journal-title":"Ann Neurol"},{"key":"15_CR63","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0006-8993(88)90765-2","volume":"451","author":"A Novelli","year":"1988","unstructured":"Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205\u2013212","journal-title":"Brain Res"},{"key":"15_CR64","first-page":"121","volume":"20","author":"J O\u2019Brien","year":"1991","unstructured":"O\u2019Brien J, Eagger S, Levy R (1991) Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer\u2019s disease. Age Ageing 20:121\u2013131","journal-title":"Age Ageing"},{"issue":"Suppl. 2","key":"15_CR65","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1007\/s100720200086","volume":"23","author":"L Parnetti","year":"2002","unstructured":"Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V (2002) Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 23(Suppl. 2):S95\u2013S96","journal-title":"Neurol Sci"},{"key":"15_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/156720510790274464","volume":"7","author":"RH Parri","year":"2010","unstructured":"Parri RH, Dineley TK (2010) Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 7:27\u201339","journal-title":"Curr Alzheimer Res"},{"key":"15_CR67","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res. http:\/\/dx.doi.org\/07\/s12640-013-9398-z"},{"key":"15_CR68","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","volume":"14","author":"ER Peskind","year":"2006","unstructured":"Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704\u2013715","journal-title":"Am J Geriatr Psychiatry"},{"key":"15_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"AP Porsteinsson","year":"2008","unstructured":"Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group (2008a) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83\u201389","journal-title":"Curr Alzheimer Res"},{"key":"15_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"AP Porsteinsson","year":"2008","unstructured":"Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008b) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83\u201389","journal-title":"Curr Alzheimer Res"},{"key":"15_CR71","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","volume":"62","author":"J Prickaerts","year":"2012","unstructured":"Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, Konig G (2012) EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099\u20131110","journal-title":"Neuropharmacology"},{"key":"15_CR72","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","volume":"76","author":"MS Rafii","year":"2011","unstructured":"Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS (2011) A phase II trial of huperzine a in mild to moderate Alzheimer disease. Neurology 76:1389\u20131394","journal-title":"Neurology"},{"issue":"8","key":"15_CR73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.arcmed.2012.11.008","volume":"43","author":"J Ramirez-Bermudez","year":"2012","unstructured":"Ramirez-Bermudez J (2012) Alzheimer\u2019s disease: critical notes on the history of a medical concept. Arch Med Res 43(8):595\u2013599","journal-title":"Arch Med Res"},{"key":"15_CR74","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","volume":"306","author":"G Rammes","year":"2001","unstructured":"Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 306:81\u201384","journal-title":"Neurosci Lett"},{"key":"15_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157015908783769671","volume":"6","author":"G Rammes","year":"2008","unstructured":"Rammes G, Danysz W, Parsons CG (2008) Pharmacodynamics of memantine: an update. Curr Neuropharmacol 6:55\u201378","journal-title":"Curr Neuropharmacol"},{"key":"15_CR76","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1016\/j.bmcl.2010.12.015","volume":"21","author":"PR Reid","year":"2011","unstructured":"Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, Days E, Daniels JS, Jones CK, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Wood MR (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg Med Chem Lett 21:2697\u20132701","journal-title":"Bioorg Med Chem Lett"},{"key":"15_CR77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1503\/jpn.110190","volume":"38","author":"TJ Revett","year":"2013","unstructured":"Revett TJ, Baker GB, Jhamandas J, Kar S (2013a) Glutamate system, amyloid peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38:6\u201323","journal-title":"J Psychiatry Neurosci"},{"key":"15_CR78","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1503\/jpn.110190","volume":"38","author":"TJ Revett","year":"2013","unstructured":"Revett TJ, Baker GB, Jhamandas J, Kar S (2013b) Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38:6\u201323","journal-title":"J Psychiatry Neurosci"},{"key":"15_CR79","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000100875","volume":"23","author":"MW Riepe","year":"2007","unstructured":"Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I (2007) Domain specific improvement of cognition on memantine in patients with Alzheimer\u2019s disease treated with rivastigmine. Dement Geriatr Cogn Disord 23:301\u2013306","journal-title":"Dement Geriatr Cogn Disord"},{"key":"15_CR80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","volume":"10","author":"SL Rogers","year":"2000","unstructured":"Rogers SL, Doody RS, Pratt RD, Ieni JR (2000) Long-term efficacy and safety of donepezil in the treatment of Alzheimer\u2019s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10:195\u2013203","journal-title":"Eur Neuropsychopharmacol"},{"key":"15_CR81","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00702-006-0579-2","volume":"113","author":"R Schliebs","year":"2006","unstructured":"Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer\u2019s disease. J Neural Transm 113:1625\u20131644","journal-title":"J Neural Transm"},{"key":"15_CR82","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"LS Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991\u2013998","journal-title":"Arch Neurol"},{"issue":"2","key":"15_CR83","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.mad.2005.09.018","volume":"127","author":"G Silvestrelli","year":"2006","unstructured":"Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F (2006) Treatment of Alzheimer\u2019s disease: from pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 127(2):148\u2013157","journal-title":"Mech Ageing Dev"},{"key":"15_CR84","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1073\/pnas.87.7.2452","volume":"87","author":"TA Slotkin","year":"1990","unstructured":"Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, Nemeroff CB (1990) Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proc Natl Acad Sci U S A 87:2452\u20132455","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR85","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317\u2013324","journal-title":"JAMA"},{"key":"15_CR86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/gps.3946","volume":"28","author":"S Todd","year":"2013","unstructured":"Todd S, Barr S, Roberts M, Passmore AP (2013) Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry 28:1109\u20131124","journal-title":"Int J Geriatr Psychiatry"},{"key":"15_CR87","first-page":"37","volume":"4","author":"J Toyohara","year":"2010","unstructured":"Toyohara J, Hashimoto K (2010) Alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer\u2019s disease. Open Med Chem J 4:37\u201356","journal-title":"Open Med Chem J"},{"issue":"12","key":"15_CR88","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bcp.2013.04.001","volume":"85","author":"TL Wallace","year":"2013","unstructured":"Wallace TL, Bertrand D (2013) Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol 85(12):1713\u20131720","journal-title":"Biochem Pharmacol"},{"key":"15_CR89","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","volume":"271","author":"PB Watkins","year":"1994","unstructured":"Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease. JAMA 271:992\u2013998","journal-title":"JAMA"},{"key":"15_CR90","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","volume":"69","author":"B Winblad","year":"2007","unstructured":"Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69:S14\u2013S22","journal-title":"Neurology"},{"key":"15_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","volume":"97","author":"Y Xu","year":"2012","unstructured":"Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, Wang Q (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog Neurobiol 97:1\u201313","journal-title":"Prog Neurobiol"},{"key":"15_CR92","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10571-007-9163-z","volume":"28","author":"HY Zhang","year":"2008","unstructured":"Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine a: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28:173\u2013183","journal-title":"Cell Mol Neurobiol"}],"container-title":["Advances in Experimental Medicine and Biology","GeNeDis 2018"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-32633-3_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:57:57Z","timestamp":1722945477000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-32633-3_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030326326","9783030326333"],"references-count":92,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-32633-3_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"29 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}